SCHEMBL1867232

SCHEMBL1867232

O=C(NCCO)c1cnc(-c2ccc3c(Nc4ccc(C(F)(F)F)cc4)ccnc3c2)c(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 17/20 0.49
RIPK2 O43353 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12664962 0.90 TRPV1 (0.42) TRPV1RIPK2
SCHEMBL1858243 0.90 TRPV1 (0.63) TRPV1
SCHEMBL1860073 0.88 TRPV1 (0.52) TRPV1
SCHEMBL1864618 0.87 TRPV1 (0.54) TRPV1
SCHEMBL1862732 0.85 TRPV1 (0.47) TRPV1
SCHEMBL1862046 0.85 TRPV1 (0.47) TRPV1RIPK2
SCHEMBL1862993 0.84 TRPV1 (0.59) TRPV1
SCHEMBL28845680 0.84 GAK (0.51) RIPK2
SCHEMBL12666699 0.81 SCN9A (0.41) TRPV1
SCHEMBL12666695 0.80 TRPV1 (0.54) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935702-B2 Substituted biaryl quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2011-05-03 US disclosed
US-7935702-B2 Substituted biaryl quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2011-05-03 US disclosed
US-20060111337-A1 Substituted biaryl quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111337-A1 Substituted biaryl quinolin-4-ylamine analogues PIGS, GPR52, GPR174 TRPV1 549/4885RIPK2 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.